TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23369067
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus craniosacral therapy
Study: 8526828
Drug: Dexedrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexedrine (10 mg)
Study: 8602776
Drug: Krypton red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton red laser photocoagulation treatment for classic CNV
Study: 8602776
Drug: Krypton red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton red laser photocoagulation treatment for classic and occult CNV
Study: 8602776
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for eyes with occult CNV but no classic CNV
Study: 1384762
Drug: GIK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK group (glucose, 0.6 g/kg/h; insulin, 0.12 U/kg/h; KCl, 0.12 mmol/kg/h)
Study: 2579598
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg t.i.d., 48 h prior to and up to 24 h following challenge with anti-IgE 1/3300 (v/v)
Study: 2579598
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg, b.i.d.
Study: 2579598
Drug: Indomethacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (oral and i.d.)
Study: 28624167
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide Implant
Study: 28624167
Drug: Systemic Corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Corticosteroid Therapy
Study: 28624167
Drug: Fluocinolone Acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide Implant (for individuals with initial visual acuity worse than 20/40)
Study: 8727452
Drug: MedX lumbar‐extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedX lumbar‐extension machine, isotonic exercises two times per week, reduced to one time per week, average length of treatment 97 days and 20 visits.
Study: 6405908
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term outpatient treatment programme of eclectic orientation
Study: 30797646
Drug: Carbohydrate reduced
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate reduced hospital diet (CRD) of 135 g/d
Study: 22213153
Drug: Enzastaurin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (loading dose 1125 mg, followed by 500 mg/d) with 5-fluorouracil/leucovorin plus bevacizumab
Study: 18306904
Drug: Methylprednisolone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (16 mg/die for the first 7 days, then 8 mg die for another 7 days, and finally 4 mg die for another 7 days) plus conventional therapy (bronchodilators and inhaled corticosteroids)
Study: 12100834
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) support intervention
Study: 18042668
Drug: Tyrosine supplementation
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine supplementation (graded intakes from 2.5 to 12.5 mg.kg(‐1).day(‐1))
Study: 12442931
Drug: Sufentanil 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 8 mL bolus, followed by infusion at 5 mL h(‐1) of a mixture containing sufentanil 1 microg mL(‐1) and bupivacaine 1 mg mL(‐1)
Study: 12442931
Drug: Fentanyl 8
Normalized name: FENTANYL 87.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 8 mL bolus, followed by infusion at 5 mL h(‐1) of a solution containing fentanyl 3.5 microg mL(‐1) and bupivacaine 1 mg mL(‐1)
Study: 9124784
Drug: Transabdominal preperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transabdominal preperitoneal laparoscopic repair (group L) with 3 x 5 inch polypropylene mesh
Study: 9124784
Drug: Transabdominal preperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transabdominal preperitoneal laparoscopic repair (group L)
Study: 6416514
Drug: overnight supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: overnight supplementary nasogastric tube feeding (4.2 MJ (1000 kcal), including 28 g protein) in addition to normal ward diet
Study: 29701878
Drug: Standard nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutrition care (hourly-rate-based protocol, without protein supplementation)
Study: 27434221
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor antagonist Exendin 9-39 (Ex-9)
Study: 19619378
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy (5 sessions over a 5-week period during postoperative radiotherapy)
Study: 19619378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no art therapy)
Study: 18827063
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) in octogenarians
Study: 18827063
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) in patients <80 years
Study: 8775472
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus ursodeoxycholic acid (900 mg/day)
Study: 8775472
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus simvastatin (40 mg/day)
Study: 2280855
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg/b.i.d./i.v.)
Study: 2280855
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 UI/t.i.d./s.c.)
Study: 367678
Drug: Atenolol alone
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol alone (100 mg twice daily)
Study: 367678
Drug: Atenolol-chlorthalidone combination
Normalized name: atenolol / chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol-chlorthalidone combination
Study: 367678
Drug: Atenolol added
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol added to chlorthalidone (100 mg twice daily)
Study: 367678
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of atenolol
Study: 27217446
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg intravenously once every 3 weeks)
Study: 27217446
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg) plus Fosbretabulin (60 mg/m(2) intravenously once every 3 weeks)
Study: 22902784
Drug: Self-administered intradermal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intradermal influenza vaccine
Study: 22902784
Drug: Nurse-administered intradermal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered intradermal influenza vaccine
Study: 24290423
Drug: Interventional fetal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional fetal medicine randomised controlled trial (RCT)
Study: 20213469
Drug: Maximal agonist
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal agonist torque estimated from resultant and antagonist torques in plantar-flexion (PF) and dorsi-flexion (DF).
Study: 10831026
Drug: Fluvoxamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine treatment (100-300 mg/day) for 10 weeks
Study: 8624271
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to 6 months of first-line chemotherapy
Study: 30610155
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice daily for 3 months)
Study: 26866364
Drug: Carvedilol 6.25
Normalized name: carvedilol 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25 mg daily during chemotherapy
Study: 24961324
Drug: Actovegin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (250 ml, 4 mg/ml) as monotherapy for 10 days
Study: 24961324
Drug: Dextranes and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextranes and pentoxyphyllin (100 mg/day)
Study: 20040339
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg under fed conditions
Study: 20040339
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg under fasted conditions
Study: 20040339
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg q.d. + Metformin 1,000 mg b.i.d.
Study: 20040339
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg q.d. + Cimetidine 400 mg q.d.
Study: 20040339
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg q.d. alone
Study: 20040339
Drug: Alogliptin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 100 mg q.d. + Metformin 1,000 mg b.i.d. and Alogliptin 100 mg q.d. + Cimetidine 400 mg q.d.
Study: 17622869
Drug: Intermittent feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent feeding regimen (one‐sixth of daily needs infused every 4 hours)
Study: 10548325
Drug: Arizona Food
Normalized name: Arizona ash pollen extract
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arizona Food Frequency Questionnaire (AFFQ) administered at baseline and year 1
Study: 7751430
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg and Hydrochlorothiazide 6.25 mg (B5/H6.25)
Study: 7751430
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg (H25)
Study: 2340838
Drug: Sinemet-controlled release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet-controlled release (CR4) 50 mg carbidopa/200 mg levodopa
Study: 30565745
Drug: Probiotics and
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics and lactoferrin (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Study: 30565745
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Study: 16953529
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg intravenous morphine
Study: 15364136
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) with cisplatin and vinorelbine; cisplatin 80 mg/m² on day 1, vinorelbine 25 mg/m² on days 1 and 4 of cycles 1 and 4, and 12.5 mg/m² during cycles 2 and 3; RT started on day 4 of cycle 2.
Study: 15364136
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy (CRT) with cisplatin and vinorelbine; same chemotherapy regimen as concurrent arm; RT started within 2 weeks after completion of chemotherapy.
Study: 15364136
Drug: Concurrent CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent CRT
Study: 15364136
Drug: Sequential CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential CRT
Study: 10714910
Drug: Micronised 17beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised 17beta oestradiol (2 mg daily) + dydrogesterone (5-20 mg for last 14 days)
Study: 1731540
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL of 5% dextrose + 1000 mL of Ringers solution (RS) + 250 mL of 5% human albumin (HA)
Study: 1731540
Drug: 1750 mL
Normalized name: ALCOHOL 1465.1 mL in 1750 mL TOPICAL LIQUID [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1750 mL of RS + 500 mL of 3.5% gelatin
Study: 1731540
Drug: 1850 mL
Normalized name: CATHETER,URETHRAL 16FR 5CC F#762-1850
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1850 mL of RS + 400 mL of 20% HA
Study: 1731540
Drug: 1750 mL
Normalized name: ALCOHOL 1465.1 mL in 1750 mL TOPICAL LIQUID [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1750 mL of RS + 500 mL of 10% low molecular weight hydroxyethyl starch
Study: 1731540
Drug: 2250 mL
Normalized name: ALCOHOL 2250 mL in 3000 mL TOPICAL LIQUID [EXIHUAN Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2250 mL of RS
Study: 31747825
Drug: OnabotulinumtoxinA injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injections combined with upper-limb physiotherapy
Study: 31747825
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections combined with upper-limb physiotherapy
Study: 22465175
Drug: Potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretics (N = 192)
Study: 19307987
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and behavioral treatment
Study: 19307987
Drug: Parent report
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent report of medication adherence
Study: 17710011
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose remifentanil (0.4 microg/kg/min)
Study: 17710011
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose remifentanil (0.1 microg/kg/min)
Study: 11558855
Drug: GP IIb/IIIa-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa-receptor inhibitors
Study: 9678793
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell factor (SCF) 20 microg/kg plus G‐CSF
Study: 9678793
Drug: SCF 20
Normalized name: Immunoglobulin scfv-scfv-scfc, anti-(homo sapiens dll3 (delta-like ligand 3)) and anti-(homo sapiens cd3e (cd3 epsilon, leu-4)), monoclonal antibody single chain (scfv)2-scfc, bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF 20 microg/kg plus G‐CSF 5 microg/kg
Study: 9678793
Drug: SCF administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCF administration
Study: 8205878
Drug: IPV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV with 2.5 mg albuterol (internal percussive component activated)
Study: 8205878
Drug: IPV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV with 2.5 mg albuterol (internal percussive component inactivated) followed by P&PD
Study: 8205878
Drug: Nebulizer with
Normalized name: AeroNeb Go Nebulizer with Cable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer with 2.5 mg albuterol followed by P&PD
Study: 2913847
Drug: Prophylactic transdermal
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic transdermal scopolamine patches
Study: 22302453
Drug: Comprehensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive periodontal treatment during pregnancy
Study: 22302453
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (one session of supragingival scaling and oral hygiene instruction after delivery)
Study: 21777233
Drug: Albendazole plus
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole plus antiepileptics
Study: 21777233
Drug: Antiepileptics only
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptics only
Study: 15651177
Drug: Lipid formulation
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulation of amphotericin B or echinocandin
Study: 31013539
Drug: Early Premature
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Premature Infant Oral Motor Intervention (PIOMI), given 15 to 30 minutes before feeding once a day for 14 days
Study: 31013539
Drug: Early Premature
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Premature Infant Oral Motor Intervention (PIOMI)
Study: 28712955
Drug: ΔRVSWI ≤1.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: ΔRVSWI ≤1.07 mm Hg⋅L⋅m-2 and ΔLVSWI ≤4.57 mm Hg⋅L⋅m-2
Study: 25528363
Drug: FGF-23 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF-23 levels above the median (395 RU/mL)
Study: 15836716
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d., amoxicillin 1 g b.d., and clarithromycin 500 mg b.d. (RAC group, n = 28)
Study: 15836716
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d., metronidazole 500 mg b.d., and tetracycline 500 mg b.d. (RMT group, n = 28)
Study: 15836716
Drug: First-line Maastricht
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line Maastricht therapy
Study: 10986030
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous platelet lysate applied twice per week for up to 9 months in combination with standardised compression bandaging
Study: 10986030
Drug: Placebo buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo buffer solution applied twice per week for up to 9 months in combination with standardised compression bandaging
Study: 1944755
Drug: Ciclosporin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin and low-dose prednisone
Study: 6864445
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (exposed to two treatments designed to reduce imitation of aggressive behaviors)
Study: 6864445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received comparable neutral treatments)
Study: 31419080
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) 1 g
Study: 19318634
Drug: Factor D
Normalized name: Factor D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor D (50 microg selenium, 30 mg vitamin E, and 15 mg beta-carotene)
Study: 11995457
Drug: IL-2 preoperative
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 preoperative immunotherapy (12 million IU/day subcutaneously for 3 consecutive days prior to surgery)
Study: 11995457
Drug: IL-2 preoperative
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 preoperative immunotherapy
Study: 10431942
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of caffeine (placebo)
Study: 30777122
Drug: Consult for
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consult for Addiction Treatment and Care in Hospitals (CATCH) model
Study: 25343955
Drug: Aryoseven (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aryoseven (90 to 120 μg/kg intravenously every 2 hours)
Study: 25343955
Drug: Novoseven (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novoseven (90 to 120 μg/kg intravenously every 2 hours)
Study: 20112413
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (laser therapy, steroid injections) for partial and nonresponders
Study: 12435698
Drug: Intravenous ARS
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ARS (2.4 mg/kg) followed by intramuscular ARS (1.2 mg/kg)
Study: 12435698
Drug: Intramuscular ARS
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ARS (2.4 mg/kg) followed by intravenous ARS (1.2 mg/kg)
Study: 12435698
Drug: Intramuscular ARS
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ARS
Study: 1955508
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week, either in the morning or in the evening for 12 months
Study: 1955508
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week
Study: 6791491
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition regimen adequate in amino acids and glucose
Study: 30728043
Drug: Practice-specific antibiotic-prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice-specific antibiotic-prescription feedback and educational outreach visit, including e-learning modules and tablet PCs with information on antibiotics.
Study: 30728043
Drug: Narrow-spectrum antibiotics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-spectrum antibiotics.
Study: 30728043
Drug: Broad-spectrum antibiotics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics.
Study: 27342514
Drug: No hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hydroxyurea therapy
Study: 25189626
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (coronary angiography and intervention if feasible)
Study: 19149822
Drug: 7-day taper
Normalized name: ZCORT 7-Day Tapered 1.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day taper
Study: 19149822
Drug: 28-day taper
Normalized name: CAPER BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day taper